UBS Group reaffirmed their sell rating on shares of Relx (LON:REL) in a research report sent to investors on Monday, Digital Look reports. The brokerage currently has a GBX 1,740 ($22.74) price objective on the stock.
Several other equities research analysts have also weighed in on the stock. Deutsche Bank reaffirmed a hold rating on shares of Relx in a report on Friday, July 26th. JPMorgan Chase & Co. upped their target price on shares of Relx from GBX 1,900 ($24.83) to GBX 1,950 ($25.48) and gave the stock an overweight rating in a report on Friday, July 26th. Barclays lowered their target price on shares of Relx from GBX 2,160 ($28.22) to GBX 2,100 ($27.44) and set an overweight rating on the stock in a report on Friday, July 26th. Liberum Capital reaffirmed a buy rating on shares of Relx in a report on Friday, July 26th. Finally, Goldman Sachs Group increased their price objective on shares of Relx from GBX 2,123 ($27.74) to GBX 2,178 ($28.46) and gave the stock a buy rating in a report on Tuesday, June 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of GBX 1,871 ($24.45).
REL opened at GBX 1,900 ($24.83) on Monday. The firm’s 50-day simple moving average is GBX 1,928.56 and its 200-day simple moving average is GBX 1,819.56. The company has a debt-to-equity ratio of 308.02, a quick ratio of 0.40 and a current ratio of 0.45. Relx has a twelve month low of GBX 1,466.50 ($19.16) and a twelve month high of GBX 2,027 ($26.49). The firm has a market cap of $36.92 billion and a price-to-earnings ratio of 24.64.
RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.